Hi, I've been an IMM holder for over 2 years now. With the Phase II 1st line NSCLC data looking promising and a significant improvement to the existing standard of care (pembro and chemo), it would be good to assume that IMM would be acquired by MSD with promising Phase III data.
Have any analysts looked at the many other combinations that pembro is being trialed with to improve its performance and extend its patent life? Is there a short list in 1st line NSCLC we should be watching for trial results?
Hi, I've been an IMM holder for over 2 years now. With the Phase...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
-0.010(4.08%) |
Mkt cap ! $344.9M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.3¢ | 23.5¢ | $408.8K | 1.709M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 1472949 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 142000 | 3 |
View Market Depth
| Last trade - 16.10pm 05/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |